NORRIS MEDICINES LIMITED

Towards Change

Factory : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 14th August, 2026

To,
Department of Corporate Services (DSC-CRD)
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Subject: **Outcome of Board Meeting held on Friday, 14th August, 2026 pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.**

Scrip Code: **524414**

Dear Sir,

With reference to above captioned subject and in continuation to the intimation letter dated August 08, 2026, we wish to inform you that, the meeting of the Board of Directors of Norris Medicines Limited ("the Company") held today, i.e., Friday, August 14, 2026 inter alia considered and approved the following:

1. Un-Audited Financial Results of the Company for the Quarter ended June 30, 2026 along with Limited Review Report of the Statutory Auditors on the said Un-audited Financial Results of the Company pursuant to Regulation 30 and 33 of the SEBI (LODR) Regulations, 2015, are enclosed herewith **Annexure A**;

   We are arranging to publish the said Financial Results in newspapers in the format prescribed under Regulation 47 of Listing Regulations.

2. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Vimal Dhirendra Shah (DIN: 01506655) as a Managing Director (Promoter and Executive) of the Company for a term of 3 (Three) consecutive years effective from September 01, 2026 till August 31, 2029 (both days inclusive), be liable to retire by rotation. The said re-appointment is subject to the approval of the Shareholders of the Company.

   Mr. Vimal Dhirendra Shah (DIN: 01506655) is not disqualified from being appointed as a Managing Director in terms of the Companies Act 2013 and has given his consent to act as a Managing Director.

Factory : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

The details required under Regulation 30 of the Listing Regulations read with applicable SEBI Circular(s) in respect of appointment of KMP, are enclosed herewith as **Annexure B.**

Board meeting's commencement time: **03:00 PM**

Board meeting's concluded time: **04:00 PM**

Kindly take the same on your record and acknowledge receipt of the same.

Thanking you.

FOR NORRIS MEDICINES LIMITED

VIMAL D SHAH
Digitally signed by VIMAL D SHAH
Date: 2026.08.14 17:05:33 +05'30'

VIMAL D. SHAH
DIRECTOR
DIN-01506655

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.
Phone: 02646-223462 Fax 02646 -250126.
email: contact@norrispharma.com. Website: www.norrispharma.com
CIN No.,L124230GJ1990PLC086581

Rs. In Lakhs

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

Sl. No.	Particulars	Quarter Ended 30.06.2026	Quarter Ended 31.03.2026	Quarter Ended 30.06.2025	Previous accounting year ended 31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	(a) Revenue from Operations	92.49	140.84	145.66	813.20
	(b) Other Income	0.00	2.07	2.38	4.54
	Total Income From Operations (Net)	**92.49**	**142.91**	**148.03**	**817.74**
2	***Expenses***				
	a. Cost of Materials Consumed	57.49	74.66	103.84	434.06
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	4.96	-30.72	-31.33	-3.60
	c. Employee Benfit Expenses	29.87	33.21	41.17	166.90
	d. Finance Costs	0.01	15.44	11.15	50.00
	e. Depreciation and Amortisation Expense	11.48	12.33	12.25	49.08
	f. Other expenditure	28.36	32.93	42.00	149.37
	Total Expenses	**132.17**	**137.85**	**179.08**	**845.82**
3	**Profit/ Loss before Tax (1-2)**	**-39.68**	**5.06**	**-31.04**	**-28.08**
4	Tax Expense **a: Current Tax**	0.00	0.00	0.00	0.00
	b: Deferred Tax	0.00	0.00	0.00	0.00
5	**Profit / Loss after Tax**	**-39.68**	**5.06**	**-31.04**	**-28.08**
6	**Other Comprehensive Income**				
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
7	**Total Comprehensive Income for the period**	-39.68	**5.06**	**-31.04**	-28.08
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.40	0.05	-0.31	-0.28

Notes:

1) *The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board* of Directors at their respective meeting held on 14.08.2026. The above results have been subjected to Audit by the Statutory Auditors of the Company

2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act,2013 read with relevant reules thereunder and in terms of Regulation 33ot the SEB (Listing Obligation and Disclosure Requirements) Regulation,2015 and SEBI circular dated 05.07.2016.

3) The Company is having one segment oly and therefore Segment Reporting is not aplicable.

4) There are no exceptional/ extraordinary items during the quarter ended 30.06.2026

5) Previous year/ period figures have been regrouped / rearranged wherever necessary to make them comperable with current periof figures.

For Norris Medicines Limited

Norris Medicines Limited

Vimal D Shah
Managing Director

Date: 14-08-2026
Place:Ankleshwar

BAHEDIA & ASSOCIATES
Chartered Accountants
SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Valia Road,
GIDC, ANKLESHWAR - 393 002. Office : (M) : 84011 20412

CA. B. L. Bahedia
(FCA., LL.B., D.T.P., B.Com.)

INDIA

Mobile No. : +91 98241 36264, 97252 20412
E-mail : bbahedia@yahoo.com/gmail.com

"Limited Review Report"

To,

Board of Directors of NORRIS MEDICINES LIMITED

We have reviewed the accompanying statement of unaudited financial results of NORRIS MEDICINES LIMITED, REGD. OFF 801/P, GIDC ESTATE, ANKLESHWAR-393002, for the period ended 30th June, 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 14/08/2026. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2400 "Engagement to Review Financial Statements", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FRN-114421W)

B. Bahedia

PLACE: ANKLESHWAR
DATE: 14/08/2026

BAHEDIA & ASSOCIATES
Ankleshwar-2
M.NO. 048066
CHARTERED ACCOUNTANTS

(CA. B.L. BAHEDIA)
PROPRIETOR
(M.NO.048066)
UDIN: - 26048066BHYRDM1930

NORRIS MEDICINES LIMITED

Factory : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Annexure B

Details with respect to Regulation 30 read with Schedule III of the Listing Regulations, SEBI Circular SEBI Circular bearing Ref. No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Name of the Managing Director	Mr. Vimal Dhirendra Shah (DIN: 01506655)
Reason for change Viz appointment, ~~Resignation, removal, death or otherwise~~	Appointment as Managing Director of the Company for a term of 3 years with effect from September 1, 2026, be liable for Retire by Rotation.
Date of Appointment /re-appointment/cessation (as applicable) & term of appointment/re-appointment	Appointment is with effect from 01st September, 2026.
Brief profile (In case of appointment)	He is a Commerce graduate with more than 15 years of experience in Business Management. He has extensive experience in managing and overseeing business operations and contributing to the overall growth and development of the Company. He is a member of the Audit Committee and the Stakeholders Relationship Committee of the Company. In view of his experience and knowledge of the business, he is proposed to be appointed as the Managing Director of the Company for the prescribed term.
Disclosure of relationship between Directors (in case of appointment)	He is not related to any of the Directors and Key Managerial Personnel of the Company.
Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with Exchange Circular dated June 20, 2018 (Affirmation that the person proposed to be appointed as Director is not debarred from holding the office by virtue of any SEBI Order or any other authority)	NA.
Affirmation that the Director being appointed is not disqualified from holding the office of director pursuant to provisions of Section 164 of the Companies Act, 2013	NA.

Factory : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

FOR NORRIS MEDICINES LIMITED

VIMAL D SHAH

Digitally signed by VIMAL D SHAH
Date: 2026.08.14
17:06:49 +05'30'

VIMAL D. SHAH
DIRECTOR
DIN-01506655